Please login to the form below

Not currently logged in
Email:
Password:

Thomas Christély steps down as Silence Therapeutics CEO after five months

Tony Sedgwick will take over from Christély, who resigns for personal reasons

Thomas Christély has resigned from his role as CEO at Silence Therapeutics after only five months.

The UK-based company, which develops gene therapeutic technology based on RNA interference, said Christély made the decision for personal reasons and will be replaced by chief business officer Tony Sedgwick.

Christély was only appointed CEO in September 2011, having previously held the role of CEO at Silence Therapeutics AG - a subsidiary of Silence formed following its merger with Atugen AG in 2005.

The company's new CEO, Sedgwick, joined Silence in September 2011 to lead a new business development team.

Prior to this role, he was CEO of UK drug-discovery firm Novacta and chair of the Norwegian biotech company Plastid.

Tony Sedgwick - Silence Therapeutics
Tony Sedgwick

His extensive career in the pharma industry has also seen him spend more than 15 years at Roche, including global head clinical operations.

Jerry Randall, chair of Silence, said Sedgwick had made a “very positive impact” since joining the company and had the right leadership skills for the role. Randall also thanked the departing Christély for his services.

In his own comment, Sedgwick declared his intentions concerning the future of Silence, singling out its investigational cancer therapy Atu027 as a product with potential against a range of tumour types.

He said: “Over the next few years, I intend to increase the commercial focus of the company, harness the RNAi therapeutics opportunity and, as a result, create substantial shareholder value.”

14th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics